Oncocyte Announces August Investor Conferences Participation
    Oncocyte Announces August Investor Conferences Participation
    News

    Oncocyte Announces August Investor Conferences Participation

    05 August 2024

    IRVINE, Calif., August 5, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August:
    · 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors.
    · Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, as well as participate in one-on-one meetings. To join the presentation, please visit the webcast available online at: https://sidoti.zoom.us/webinar/register/WN_rqHxQLa-SP-7yjOy-Qditw
    For additional details about the conferences or to schedule a one-on-one meeting with Oncocyte’s management team, please contact your Needham or Sidoti representative, or reach out directly to the company’s IR contact, jramson@pcgadvisory.com.
    About Oncocyte
    Oncocyte is a molecular diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
    VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/

    VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/

    GraftAssure™ - https://oncocyte.com/graftassure/

    DetermaIO™ - https://oncocyte.com/determa-io/

    DetermaCNI™ - https://oncocyte.com/determa-cni/
    VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
    CONTACT:
    Jeff Ramson

    PCG Advisory

    (646) 863-6893
    jramson@pcgadvisory.com
    Source: Oncocyte
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.